Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics
- PMID: 20050980
- DOI: 10.1111/j.1471-4159.2009.06554.x
Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics
Abstract
There is much evidence to suggest that G protein coupled receptors exist as oligomers but the relevance to their function is unclear. We have, therefore, examined the binding of the radiolabelled agonist [(3)H]NPA to membranes of CHO cells expressing the D(2) dopamine receptor in dissociation rate experiments. When [(3)H]NPA dissociation was started by dilution, the dissociation rate in the absence of sodium ions was unaffected by addition of the antagonist/inverse agonist (+)-butaclamol, but was accelerated by addition of agonists e.g. dopamine, suggesting that the receptor was not behaving as a monomer with a single binding site. The very low efficacy partial agonist, aripiprazole provided an intermediate level of acceleration of dissociation. [(3)H]NPA dissociation experiments started by addition of ligands without dilution gave a similar pattern. [(3)H]NPA dissociation could also be accelerated by GTP. Dissociation of [(3)H]NPA in the presence of GTP and dopamine provided a greater acceleration than for either modulator alone, suggesting synergistic effects related to receptor/G protein interaction. When [(3)H]NPA dissociation experiments were performed in the presence of sodium ions, dissociation was faster than in their absence but the rate still depended on the ligand present in the assay. Overall the data cannot be explained by a ternary complex model and are consistent with an oligomeric receptor in which binding of [(3)H]NPA, as an example of an agonist ligand, can be modulated co-operatively by ligands binding elsewhere in the oligomer. Interactions with G proteins also occurs providing further modulation of [(3)H]NPA binding. Both agonists and G proteins are proposed to modulate the oligomer by switching high affinity agonist binding sites to low affinity sites.
Similar articles
-
Mechanisms of inverse agonist action at D2 dopamine receptors.Br J Pharmacol. 2005 May;145(1):34-42. doi: 10.1038/sj.bjp.0706073. Br J Pharmacol. 2005. PMID: 15735658 Free PMC article.
-
Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.Biochem Pharmacol. 2004 May 1;67(9):1657-65. doi: 10.1016/j.bcp.2003.12.030. Biochem Pharmacol. 2004. PMID: 15081865
-
D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.Synapse. 2010 Aug;64(8):624-33. doi: 10.1002/syn.20771. Synapse. 2010. PMID: 20340171
-
Agonism and inverse agonism at dopamine D2-like receptors.Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S3-9. Clin Exp Pharmacol Physiol Suppl. 1999. PMID: 10386247 Review.
-
Oligomers of D2 dopamine receptors: evidence from ligand binding.J Mol Neurosci. 2005;26(2-3):155-60. doi: 10.1385/JMN:26:2-3:155. J Mol Neurosci. 2005. PMID: 16012188 Review.
Cited by
-
Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?Biochem Pharmacol. 2012 Jan 15;83(2):193-8. doi: 10.1016/j.bcp.2011.09.008. Epub 2011 Sep 16. Biochem Pharmacol. 2012. PMID: 21945484 Free PMC article. Review.
-
The Kinetic Component in Drug Discovery: Using the Most Basic Pharmacological Concepts to Advance in Selecting Drugs to Combat CNS Diseases.Curr Neuropharmacol. 2020;18(3):250-257. doi: 10.2174/1570159X17666191001144309. Curr Neuropharmacol. 2020. PMID: 31573886 Free PMC article. Review.
-
Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.Br J Pharmacol. 2010 Nov;161(6):1343-50. doi: 10.1111/j.1476-5381.2010.01010.x. Br J Pharmacol. 2010. PMID: 20804495 Free PMC article.
-
Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D2 Receptor.ACS Chem Neurosci. 2025 Jun 18;16(12):2295-2311. doi: 10.1021/acschemneuro.5c00105. Epub 2025 May 15. ACS Chem Neurosci. 2025. PMID: 40372152 Free PMC article.
-
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.J Huntingtons Dis. 2018;7(1):1-16. doi: 10.3233/JHD-170267. J Huntingtons Dis. 2018. PMID: 29480206 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources